CD44 and metastatic malignant neoplasm: Similarly, circulating tumor cells (CTCs), commonly observed in the blood/lymph systems of metastatic cancer patients, express high levels of CD44 on their surface, ultimately underscoring the enhanced tumorigenesis, metastasis, treatment resistance, and immune evasion properties of tumor‐associated CD44‐positive cells [28, 29].